Abstract |
Papillary serous carcinoma of the endometrium exhibits many clinical features of ovarian cancer, including a high metastatic potential and response to platinum-based chemotherapy. We investigated the clinical utility of the serum CA-125 antigen level, an established marker of response or progression in ovarian cancer, to serve as a indicator of these events in patients with this highly malignant subtype of endometrial cancer. Of 21 individuals with this cancer treated in our program from 11/91 to 6/97, 16 had baseline CA-125 determinations prior to the administration of chemotherapy, of whom 13 were elevated above the normal range. Of these 13 patients, 8 (57%) experienced either a major reduction or normalization of CA-125 levels following therapy, consistent with their clinical course at that point in time. Similarly, of 11 patients who ultimately relapsed, 8 (73%) were found to have a rise in the CA-125 antigen level which closely corresponded to, or proceeded, clinical relapse. A single patient was demonstrated to have disease progression with a declining level of CA-125. We conclude the serum CA-125 antigen level is a useful indicator of disease response or progression in individuals with papillary serous carcinoma of the endometrium.
|
Authors | D Abramovich, M Markman, A Kennedy, K Webster, J Belinson |
Journal | Journal of cancer research and clinical oncology
(J Cancer Res Clin Oncol)
Vol. 125
Issue 12
Pg. 697-8
(Dec 1999)
ISSN: 0171-5216 [Print] Germany |
PMID | 10592103
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Biomarkers, Tumor
- CA-125 Antigen
|
Topics |
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(therapeutic use)
- Biomarkers, Tumor
(blood)
- CA-125 Antigen
(blood)
- Cystadenocarcinoma, Papillary
(blood, drug therapy, surgery)
- Disease Progression
- Female
- Humans
- Middle Aged
- Neoplasm Recurrence, Local
- Retrospective Studies
- Uterine Neoplasms
(blood, drug therapy, surgery)
|